Clinical trials: Spondylarthritis
Axial Spondyloarthritis
A Study of Brodalumab in Subjects With Axial Spondyloarthritis (axSpA)
To evaluate the efficacy of Brodalumab in axSpA (ankylosing spondylitis [AS] and non-radiographic axial spondyloarthritis [nr-axSpA]) subjects compared to placebo, as measured by the proportion of axSpA subjects achieving an…
- Trial name
- NCT02985983
- Testing
- Brodalumab
- Where
- 48 sites in Japan, South Korea and 1 more
- Volunteers
- 159 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Autoimmune Diseases, Rheumatoid Arthritis (RA)
Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease
This is a multi-center, open-label Ph 1b basket study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, biomarker response, and preliminary efficacy of multiple doses of S-4321 in…
- Conditions
- Autoimmune Diseases, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Psoriasis (PsO)
- Trial name
- NCT07455578
- Testing
- S-4321
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Seismic Therapeutic AU Pty Ltd
Psoriatic Arthritis
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin. The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over…
- Trial name
- NCT07286058
- Testing
- Zasocitinib
- Where
- 78 sites in United States, Australia and 14 more
- Volunteers
- 1,182 people
- Sponsor
- Takeda
Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database
The purpose of this study is to expand on the ongoing post-marketing monitoring of abatacept to include all participants with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with abatacept captured in Danish…
- Trial name
- DANBIO (NCT05421442)
- Where
- United States
- Volunteers
- 38,396 people
- Sponsor
- Bristol-Myers Squibb
Spondyloarthritis
SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis
The purpose of the study was to evaluate the efficacy and safety of secukinumab 150 mg compared to placebo in the early management (Baseline to Week 8) of spinal pain, disease activity, fatigue, and predictability of disease…
- Trial name
- SKIPPAIN (NCT03136861)
- Testing
- AIN457
- Where
- 66 sites in Belgium, Bulgaria and 15 more
- Volunteers
- 383 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
To evaluate efficacy, safety, tolerability, and immunogenicity of AbGn-168H administered intravenously in patients with active psoriatic arthritis.
- Trial name
- NCT02267642
- Testing
- AbGn-168H
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- AbGenomics B.V Taiwan Branch
Ankylosing Spondylitis
A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo
The goal of this clinical trial is evaluating the efficacy and safety of Jitongning tablets in participant population. The main questions it aims to answer are: Based on the proportion of participants who achieved improvement in…
- Trial name
- NCT06000956
- Testing
- Jitongning tablets, a simulated agent of Jitongning tablets
- Where
- 10 sites in China
- Volunteers
- 408 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Ankylosing Spondylitis
A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis
This is a multi-center, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of ENIA11 in patients with ankylosing spondylitis.
- Trial name
- NCT02685904
- Testing
- ENIA11
- Where
- 6 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- Mycenax Biotech Inc.
Psoriasis
Psoriasis Longitudinal Assessment and Registry
The purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and guselkumab in patients with plaque and other forms of psoriasis.
- Trial name
- PSOLAR (NCT00508547)
- Where
- 320 sites in United States, Argentina and 20 more
- Volunteers
- 20,167 people
- Sponsor
- Janssen Scientific Affairs, LLC
Axial Spondyloarthritis, Ankylosing Spondylitis
Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy
The goal of this clinical trial is to find out if the study drug will work as a new therapy for axSpA patients. This study is placebo-controlled, and evaluates if study drug can treat symptoms of axSpA, including global disease…
- Conditions
- Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpA, Nr-axSpA
- Trial name
- V-SPINE (NCT06526377)
- Testing
- vilamakitug
- Volunteers
- 150 people
- Sponsor
- XBiotech, Inc.
Psoriatic Arthritis
A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis
Randomized, double-blind, 24-week study of patients with psoriatic arthritis comparing alefacept + methotrexate (MTX) vs. placebo + MTX followed by a 24-week open-label extension with only alefacept + MTX treatment.
- Trial name
- NCT00659412
- Testing
- Alefacept, Methotrexate
- Where
- 27 sites in United States, Canada and 3 more
- Volunteers
- 185 people
- Sponsor
- Astellas Pharma Inc
Rheumatoid Arthritis, Psoriatic Arthritis
A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia
The main objective of this post-authorization safety study is to assess healthcare professionals' awareness, knowledge, and behavior related to receipt and reading of the Direct Healthcare Professional Communication and…
- Trial name
- ARAVA PASS (NCT06714461)
- Testing
- Leflunomide
- Where
- France
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Sanofi
Rheumatoid Arthritis, Ankylosing Spondylitis
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
The aim of this post-marketing observational study is to obtain further data on the evaluation of quality of life outcomes of HUMIRA® in routine clinical use in patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT01083693
- Where
- 20 sites in Austria
- Volunteers
- 162 people
- Sponsor
- Abbott
Ankylosing Spondylitis
A Study Of Celecoxib Versus Diclofenac In Patients With Ankylosing Spondylitis
A clinical trial to assess the effect of celecoxib 200 milligrams (mg) once daily and 400 milligrams (mg) once daily compared to diclofenac three times daily in the treatment of Ankylosing Spondylitis (AS) for 12 weeks.
- Trial name
- NCT02528201
- Testing
- Celecoxib 200 milligrams, Celecoxib 400 milligrams, diclofenac 50 milligrams
- Where
- 27 sites in Norway
- Volunteers
- 330 people
- Sponsor
- Pfizer
Crohn's Disease, Ulcerative Colitis (UC)
Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
This study aims to evaluate the impact of AbbVie Care 2.0 on adalimumab's compliance, patient reported outcomes and utilization of health resources over 12 months.
- Conditions
- Crohn's Disease, Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), Psoriatic Arthritis
- Trial name
- IMPROVE (NCT03223012)
- Where
- 15 sites in Portugal
- Volunteers
- 116 people
- Sponsor
- AbbVie
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis
This was an observational, prospective primary data collection study. The duration of observation was 2 years after study enrolment date.
- Conditions
- Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
- Trial name
- PROMPT (NCT05155098)
- Testing
- secukinumab
- Where
- 10 sites in Thailand
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis
A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis
This is a study to evaluate the efficacy and safety of different doses of bimekizumab in subjects with active Ankylosing Spondylitis (AS).
- Trial name
- BE AGILE (NCT02963506)
- Testing
- Bimekizumab
- Where
- 74 sites in United States, Bulgaria and 8 more
- Volunteers
- 303 people
- Sponsor
- UCB Biopharma S.P.R.L.
Ankylosing Spondylitis
Work Productivity in Active Ankylosing Spondylitis (AS) Patients Treated With Enbrel.
Patients with Ankylosing spondylitis more frequently discontinue work. This study measures the impact of Enbrel on work participation.
- Trial name
- AS@WORK (NCT01421303)
- Testing
- Enbrel
- Where
- Belgium
- Volunteers
- 80 people
- Sponsor
- Pfizer
Psoriatic Arthritis
A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)
To further assess the safety and effectiveness of adalimumab 40mg in the treatment PsA who have had an unsatisfactory response or intolerance to prior or ongoing DMARDs
- Trial name
- NCT00427362
- Testing
- Adalimumab
- Volunteers
- 127 people
- Sponsor
- Abbott
Ankylosing Spondylitis, Psoriatic Arthritis
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
This 12-month postmarketing observational study (PMOS) was a prospective, single-arm, multicenter, multi-country study, with follow-up visits at 3, 6, 9, and 12 months after the initial baseline visit.
- Trial name
- NCT01474876
- Volunteers
- 566 people
- Sponsor
- AbbVie (prior sponsor, Abbott)